Cantor maintains BioMarin stock overweight with $90 target

On Friday, Cantor Fitzgerald reaffirmed its positive stance on BioMarin Pharmaceutical (TADAWUL:2070) Inc. (NASDAQ:BMRN), maintaining an Overweight rating and a $90.00 price target. Currently trading at $61.26, InvestingPro analysis suggests the stock is undervalued, with analyst targets ranging from $65 to $126. The endorsement follows the company’s recent earnings report, which surpassed expectations. BioMarin also confirmed its full-year earnings per share (EPS) guidance to be in the range of $4.20 to $4.40, indicating a year-over-year growth of 19-25%.

BioMarin’s financial performance has been strong, with the company delivering another earnings beat. The company’s impressive 17.97% revenue growth and healthy gross margin of 79.67% underscore its robust business model. Although the company cautioned that EPS might show variability from quarter to quarter, the reaffirmed guidance suggests a steady growth trajectory. Analysts at Cantor Fitzgerald are forecasting that BioMarin will continue to experience double-digit earnings growth through to 2029.

The company’s operating margins are also expected to improve significantly. Current projections for 2025 anticipate operating margins between 31% and 33%, with the potential to exceed 40% in the subsequent years. This improvement in margins is anticipated to contribute to the company’s financial strength and stability, which is already reflected in its excellent current ratio of 5.33 and moderate debt levels.

The positive outlook from Cantor Fitzgerald is based on BioMarin’s consistent performance and the expectation of continued earnings growth. The company’s focus on delivering strong financial results is reflected in the analyst’s projection of increasing profitability over the coming years.

BioMarin’s stock remains a focus for investors looking for growth in the pharmaceutical sector, as indicated by the maintained Overweight rating and price target. The company’s ability to meet and exceed earnings expectations while providing clear guidance for the future positions it as a noteworthy player in the industry.

In other recent news, BioMarin Pharmaceutical Inc. reported strong financial results for the first quarter of 2025, surpassing Wall Street’s expectations. The company achieved earnings per share of $1.13, significantly exceeding the forecasted $0.70, and generated revenue of $745 million, beating the anticipated $741.02 million. Notably, BioMarin’s revenue grew by 15% year-over-year, driven by the success of its product VOXZOGO, which saw a 40% increase in global revenue. Furthermore, BioMarin’s operating cash flow rose by 271% from the previous year, highlighting its robust financial health.

In terms of analyst activity, several firms have taken note of BioMarin’s performance, reflecting confidence in the company’s growth trajectory. BioMarin has also projected full-year VOXZOGO revenue between $900 million and $950 million, aiming for a 26% growth. The company is focused on innovation and expansion, with plans to achieve a $4 billion revenue target by 2027. These developments underscore BioMarin’s strategic emphasis on genetically defined conditions and its efforts to mitigate potential impacts from pharmaceutical tariffs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.